


DOCKET NO. TOS-123-USA-C

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this supplemental amendment, transmittal and journal article, our Docket No. TOS-123-USA-C, Serial No. 09/147,237 is being transmitted via facsimile to the United States Patent and Trademark Office at 703-305-3014 and 703-305-7939, to the attention of Examiner Fernando Prats, in Art Unit 1651, on February 27, 2002.

Donald E. Townsend



TOWNSEND & BANTA
INTELLECTUAL PROPERTY LAW & LITIGATION
#50028
SUITE 500
1225 EYE STREET, N.W.
WASHINGTON, D.C. 20005 U.S.A.

TELEPHONE 202-682-4727

FACSIMILE 301-754-6495

*** **FACSIMILE TRANSMISSION COVER SHEET** ***

DATE: February 27, 2002

E.D.T. (U.S.A.)

TO:

FAX NO.: 703-305-7939

Name: Examiner Fernando Prats
Art Unit 1651
U.S. PTO

FROM:

FAX NO.: 301-754-6495

Name: Donald E. Townsend, Esq.
TOWNSEND & BANTA
1225 Eye Street, N.W., Suite 500
Washington, D.C. 20005

TOTAL NUMBER OF SHEETS INCLUDING THIS PAGE: 12

Comments:

IF YOU DO NOT RECEIVE ALL SHEETS, PLEASE CALL (301) 681-5948.**** CONFIDENTIALITY NOTE ****

The documents accompanying this telecopy transmission contain information from the Law Offices of Townsend & Banta, which is confidential or privileged. The information is intended to be for the use by the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this telecopied information is prohibited. If you have received this telecopy in error, please notify us by telephone immediately.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE THE APPLICATION OF: E. Yagi, et al.

SERIAL NO.: 09/147,237

GROUP: 1651

FILED: April 20, 1999

EXAMINER: F. Prats

TITLE: Immunopotentiators

THE COMMISSIONER OF PATENTS
AND TRADEMARKS
WASHINGTON, D.C. 20231

SIR:

TRANSMITTED HERewith IS AN ☒ SUPPLEMENTAL AMENDMENT, ☐ REPLY, ☐ AMENDMENT AFTER FINAL REJECTION
IN THE ABOVE-IDENTIFIED APPLICATION.

☐ Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

☒ No additional fee is required.

THE FEE HAS BEEN CALCULATED AS SHOWN BELOW:

CLAIMS	REMAINING AFTER AMENDMENT		HIGH.# PREV. PAID FOR	PRESENT EXTRA	SMALL ENTITY RATE ADD'L FEE	OTHER THAN A SMALL ENTITY RATE ADD'L FEE
TOTAL	7	MINUS	20	= 0	X9=\$	X18=\$0
INDEP.	3	MINUS	3	= 0	X39=\$	X78=\$0

<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM		+130=\$	+260=\$
	TOTAL ADD'L FEE		-0-


☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 20-1424. A duplicate copy of this sheet is attached.

- ☒ Any additional filing fees under 37 C.F.R. 1.16 for the presentation of extra claims.
☒ Any patent application processing fees under 37 C.F.R. 1.17.
☒ Any extensions of time under 37 C.F.R. 1.17.

☐ Please charge my deposit account No. 20-1424 in the amount of \$

☐ A check in the amount \$ -0- is attached.

Date: February 27, 2002


Donald E. Townsend
Attorney of Record
Registration No. 22,069

TOWNSEND & BANTA
1225 Eye Street, N.W.
Suite 500, #50028
Washington, D.C. 20005
(202) 682-4727

#336/11

02-28-02

DOCKET NO. TOS-123-USA-C N.E.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
E. YAGI, et al.

Serial No.: 09/147,237

Art Unit: 1651

Filed: April 20, 1999

Examiner: F. Prats

For: Immunopotentiators

SUPPLEMENTAL AMENDMENT AFTER FINAL REJECTION

NON-FEE AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Responsive to the official final Office Action mailed December 10, 2001, and supplemental to the Response mailed on February 11, 2002, and faxed to the Examiner on February 25, 2002, in the matter of the above-identified application, kindly amend the same as follows:

Kindly add new Claim 18 as follows:

18. A method of treatment for prevention against the suppression of the antigen presentation function of Langerhans' cells due to UV irradiation, comprising applying to the skin a composition comprising glutathione.

NOTED
SEP 3-4-02